secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001171843-24-004479
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus reports Q2 loss; soquelitinib shows early activity in atopic derm, PTCL Phase 3 on track
--------------------------------------------------------------------------------

- Early soquelitinib Phase 1 atopic dermatitis data (3 evaluable patients, 100 mg BID) show clinical activity and cytokine changes consistent with ITK inhibition.
- Phase 3 registrational trial for soquelitinib in PTCL to start Q3 2024; updated Phase 1/1b data: 39% ORR (6 CRs, 3 PRs) in 23 evaluable patients.
- Cash, cash equivalents and marketable securities $47.2M as of June 30, 2024; Q2 2024 net loss $4.3M vs $6.5M prior year; cash runway into Q4 2025.
- Ciforadenant Phase 1b/2 trial in RCC met interim efficacy threshold; enrollment continues. New U.S. patent issued for ciforadenant.
- Soquelitinib received Fast Track designation for relapsed/refractory PTCL; FDA pediatric waiver granted for T cell lymphoma indication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184324004479/0001171843-24-004479-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184324004479/f8k_080624.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-004479

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer